New pill tested to control rare hormone disorder

NCT ID NCT05192382

Ongoing Disease control Sponsor: Crinetics Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new oral medication called paltusotine can safely control the hormone levels and symptoms of acromegaly. It involves 111 adults with acromegaly who are not currently on other drug treatments. Participants are randomly assigned to receive either the real drug or a placebo pill to compare the results.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Crinetics Study Site

Aurora, Colorado, 80045, United States
Crinetics Study Site

Boston, Massachusetts, 02114, United States
Crinetics Study Site

Columbus, Ohio, 43210, United States
Crinetics Study Site

Portland, Oregon, 97239, United States
Crinetics Study Site

Philadelphia, Pennsylvania, 19104, United States
Crinetics Study Site

Pittsburgh, Pennsylvania, 15213, United States
Crinetics Study Site

CABA, Buenos Aires, C1012AAR, Argentina
Crinetics Study Site

Buenos Aires, C1405BCH, Argentina
Crinetics Study Site

CABA, 1425, Argentina
Crinetics Study Site

CABA, C1199ABB, Argentina
Crinetics Study Site

Córdoba, X5000, Argentina
Crinetics Study Site

Fortaleza, Ceará, 60430-275, Brazil
Crinetics Study Site

Belo Horizonte, Minas Gerais, 30130100, Brazil
Crinetics Study Site

Curitiba, Paraná, 80030-110, Brazil
Crinetics Study Site

Botucatu, São Paulo, 18618-686, Brazil
Crinetics Study Site

Campinas, São Paulo, 13060-904, Brazil
Crinetics Study Site

Rio de Janeiro, 20231-092, Brazil
Crinetics Study Site

São Paulo, 05403-000, Brazil
Crinetics Study Site

São Paulo, 1228000, Brazil
Crinetics Study Site

Sofia, 1431, Bulgaria
Crinetics Study Site

Guangzhou, Guangdong, 510080, China
Crinetics Study Site

Shijiazhuang, Hebei, 050000, China
Crinetics Study Site

Zhengzhou, Henan, 450000, China
Crinetics Study Site

Wuhan, Hubei, 430030, China
Crinetics Study Site

Changsha, Hunan, 410003, China
Crinetics Study Site

Jinan, Shandong, 250063, China
Crinetics Study Site

Xi’an, Shanxi, 710032, China
Crinetics Study Site

Chengdu, Sichuan, 610041, China
Crinetics Study Site

Hangzhou, Zhejiang, 310009, China
Crinetics Study Site

Marseille, 13395, France
Crinetics Study Site

Pessac, 33604, France
Crinetics Study Site

Toulouse, 31400, France
Crinetics Study Site

Aachen, 52074, Germany
Crinetics Study Site

Berlin, 10117, Germany
Crinetics Study Site

München, 80336, Germany
Crinetics Study Site

München, 81667, Germany
Crinetics Study Site

Würzburg, 97080, Germany
Crinetics Study Site

Athens, 10676, Greece
Crinetics Study Site

Thessaloniki, 54642, Greece
Crinetics Study Site

Budapest, 1062, Hungary
Crinetics Study Site

Budapest, 1083, Hungary
Crinetics Study Site

Pécs, 7624, Hungary
Crinetics Study Site

Bangalore, Karnataka, 560054, India
Crinetics Study Site

Belagavi, Karnataka, 590010, India
Crinetics Study Site

Kochi, Kerala, 682041, India
Crinetics Study Site

Mumbai, Maharashtra, 400012, India
Crinetics Study Site

Chandigarh, 160012, India
Crinetics Study Site

Delhi, 110029, India
Crinetics Study Site

Petah Tikva, 4941492, Israel
Crinetics Study Site

Roma, 00168, Italy
Crinetics Study Site

Bydgoszcz, 85-605, Poland
Crinetics Study Site

Poznan, 60-355, Poland
Crinetics Study Site

Wroclaw, 50-367, Poland
Crinetics Study Site

Barcelona, 08035, Spain
Crinetics Study Site

London, EC1M 6BQ, United Kingdom
Crinetics Study Site (b)

Beijing, Beijing Municipality, 100730, China
Crinetics Study Site (b)

Athens, 11527, Greece

Conditions

Explore the condition pages connected to this study.

ACROMEGALY